Yükleniyor... / Loading...
This observational study evaluates the effectiveness and prognosis of microwave ablation in patients with papillary thyroid microcarcinoma (a small thyroid cancer), assessed using contrast-enhanced ultrasound together with an 88-gene panel test for thyroid cancer. It is open to patients aged 18-70 with low-risk microcarcinoma who choose either microwave ablation or surgery. It is a study without an assigned phase and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Aged 18-70 years, gender not specified; * Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood); * Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery; * Patients voluntarily choose to undergo microwave ablation therapy or surgical resection. Exclusion Criteria: * Tumor located in the isthmus of the thyroid; * Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid/insular subtype, oncocytic subtype); * Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months); * Pregnant women, lactating women; * Patients with severe coagulation disorders; * Patients with contralateral vocal cord dysfunction; * Patients with contraindications to ultrasound contrast agents; * Other conditions deemed ineligible for enrollment by the investigator.